HPV Detection Patent Gets FDA Limbo Extension
Published Date: 11/28/2025
Notice
Summary
Gen-Probe Inc. just scored a one-year interim extension on their U.S. Patent for the Aptima® HPV Assay with the Panther® System because FDA approval is still in progress. This means the patent now lasts longer, giving the company more time to protect and profit from their medical device. The extension kicks in right after the original patent expires on December 8, 2025.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
One-Year Patent Extension Granted
The U.S. Patent and Trademark Office granted a one-year interim extension of U.S. Patent No. 8,785,125 for the Aptima® HPV Assay with the Panther® System. The extension begins at the patent's original expiration date, December 8, 2025, and lasts one year (through December 8, 2026), under 35 U.S.C. 156(d)(5) because FDA approval (PMA 100042/S038) is still pending.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2025-21410, Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Title-Identifying/Marking Explosive Materials
The ATF is updating how they collect info about marking explosive materials and wants your feedback by January 27, 2026. This affects businesses and agencies handling explosives, aiming to make paperwork clearer and easier without extra costs. They’re making sure the rules stay useful and not too time-consuming for everyone involved.
Next: 2025-21412, Agency Information Collection Activities; Comment Request on U.S. Withholding Tax Return for Disposition by Foreign Persons of U.S. Real Property Interests and Statement of Withholding on Dispositions by Foreign Persons of U.S. Real Property Interests
The IRS wants your thoughts on the forms foreign people use when selling U.S. real estate and paying taxes on it. If you’re a foreign seller or help them, this could affect you by possibly changing paperwork or deadlines. Send your comments by January 27, 2026, to help shape how the IRS collects this info and maybe make things easier!